CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Status Terminated

Clinical Trial Summary

The current standard of care for the frontline treatment of peripheral T-cell lymphomas (PTCL) is induction chemotherapy followed by autologous stem cell transplantation (ASCT). However, many patients are unable to get to ASCT or relapse after ASCT, with a poor prognosis. Recently, a novel ASCT conditioning regimen of gemcitabine, busulfan and melphalan (Gem/Bu/Mel) has been reported to lead to favorable outcomes in this disease. We therefore designed a frontline regimen of CHOEP induction followed by Gem/Bu/Mel ASCT, and report the results of a phase 2 study of this regimen in patients with PTCL.

Clinical Trial Description

Objectives: Primary - To estimate the proportion of patients alive and progression-free at 24 months after beginning induction therapy Secondary - To estimate the response rate (complete remission (CR) and partial remission (PR)) after CHOEP x 6 and after Gem/Bu/Mel ASCT - To estimate overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM) - To estimate the toxicity (grade 3 and above) - To estimate the rate of successful stem cell mobilization after CHOEP in responding patients - To estimate the proportion of patients who can successfully complete the entire treatment regimen - To estimate the time to engraftment of neutrophil and platelet engraftment after ASCT - To determine whether tumor DNA can be detected in peripheral blood of patients before therapy - To evaluate the changes and prognostic relevance in detectable tumor DNA in peripheral blood after induction chemotherapy (CHOEP) and after Gem/Bu/Mel ASCT ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01746173
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Terminated
Phase	Phase 2
Start date	July 2013
Completion date	October 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00992446` - Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma	Phase 2
Recruiting	`NCT04774068` - Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas	Phase 1
Completed	`NCT03263637` - Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies	Phase 1
Recruiting	`NCT05377827` - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT01919619` - Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies	Phase 2
Active, not recruiting	`NCT03061188` - Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes	Phase 1
Completed	`NCT03833180` - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)	Phase 1
Terminated	`NCT03195010` - Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia	Phase 2
Completed	`NCT00723099` - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Phase 2
Completed	`NCT02424968` - CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma	Phase 2
Recruiting	`NCT05127135` - Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies	Phase 1
Completed	`NCT00880815` - Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant	Phase 1
Active, not recruiting	`NCT03333486` - Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer	Phase 2
Recruiting	`NCT02859402` - Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas	Phase 2
Recruiting	`NCT04594135` - Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies	Phase 1
Recruiting	`NCT04934774` - Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances	Phase 1